Prognostic value of DAXX/ATRX loss of expression and ALT activation in PanNETs: is it time for clinical implementation? Comment

GUT

BMJ PUBLISHING GROUP

1. Marie Heim-Vogtlin SNF [PMPDP3_164484]
2. Tumour Forschung Bern
3. Swiss National Science Foundation (SNF) [PMPDP3_164484] Funding Source: Swiss National Science Foundation (SNF)